Patients with refractory and bortezomib-resistant MM exhibit the downregulated expression of X-box binding protein 1 (XBP1), an ER stress regulator, and loss-of-function mutations of XBP1 promote bortezomib resistance in patients with MM [14,15]. This evidence concerns the gene XBP1 and Miyoshi myopathy.